Evidence map›Paper›PMID 30514328›Full record

ArticleJournal of experimental & clinical cancer research : CR2018

Promoter hypomethylation mediated upregulation of MicroRNA-10b-3p targets FOXO3 to promote the progression of esophageal squamous cell carcinoma (ESCC).

Yi-Fang Lu, Jia-Rui Yu, Zhao Yang, Guan-Xia Zhu, Peng Gao, Huan Wang, Si-Yuan Chen, Jie Zhang, Mei-Yue Liu, Yi Niu and 6 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 49 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 2 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Novel milestones for early esophageal carcinoma: From bench to bed.World journal of gastrointestinal oncology · 2024
    Article
  9. Review
  10. Article
  11. Review
  12. Roles of oncogenes in esophageal squamous cell carcinoma and their therapeutic potentials.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. The Advances in Epigenetics for Cancer Radiotherapy.International journal of molecular sciences · 2022
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Yi-Fang LuDepartment of medicine, Tangshan gongren Hospital, Tangshan, China.
Jia-Rui YuDepartment of Radiation Oncology, North China University of Science and Technology Affiliated People's Hospital, Shengli Road, Tangshan, 063000, China.
Zhao YangDepartment of Radiation Oncology, North China University of Science and Technology Affiliated People's Hospital, Shengli Road, Tangshan, 063000, China.
Guan-Xia ZhuZhejiang Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, 310022, China.
Peng GaoDepartment of Radiation Oncology, North China University of Science and Technology Affiliated People's Hospital, Shengli Road, Tangshan, 063000, China.
Huan WangDepartment of Radiation Oncology, North China University of Science and Technology Affiliated People's Hospital, Shengli Road, Tangshan, 063000, China.
Si-Yuan ChenDepartment of Radiation Oncology, North China University of Science and Technology Affiliated People's Hospital, Shengli Road, Tangshan, 063000, China.
Jie ZhangDepartment of pathology, North China University of Science and Technology Affiliated People's Hospital, Tangshan, China.
Mei-Yue LiuDepartment of Radiation Oncology, North China University of Science and Technology Affiliated People's Hospital, Shengli Road, Tangshan, 063000, China.
Yi NiuDepartment of Radiation Oncology, North China University of Science and Technology Affiliated People's Hospital, Shengli Road, Tangshan, 063000, China.
Xiao-Mei WeiDepartment of Radiation Oncology, North China University of Science and Technology Affiliated People's Hospital, Shengli Road, Tangshan, 063000, China.
Wei WangDepartment of Radiation Oncology, North China University of Science and Technology Affiliated People's Hospital, Shengli Road, Tangshan, 063000, China.
Feng-Jin YeDepartment of Radiation Oncology, North China University of Science and Technology Affiliated People's Hospital, Shengli Road, Tangshan, 063000, China.
Li-Xin ZhangDepartment of Radiation Oncology, North China University of Science and Technology Affiliated People's Hospital, Shengli Road, Tangshan, 063000, China.
Yue ZhaoZhejiang Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, 310022, China. zhaoyue@zjcc.org.cn.
Guo-Gui SunDepartment of Radiation Oncology, North China University of Science and Technology Affiliated People's Hospital, Shengli Road, Tangshan, 063000, China. guogui_sun2013@163.com.
North China University of Science and Technology · CNTangshan Gongren Hospital · CNWenzhou Medical University · CNZhejiang Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEsophageal cancer is a high incident cancer worldwide with poor survival and limited therapeutic options. Alterations of microRNAs are common in cancers, and many of these micro RNAs are potential therapeutic and diagnostic targets to treat these cancers. miR-10b-3p located in chromosome region 2q31.1, and its expression is frequently increased in esophageal squamous cell carcinoma (ESCC). However, the biological functions, clinical significance and therapeutic implications of miR-10b-3p in ESCC remain unclear.

methodsThe expression levels of miR-10b-3p in ESCC specimens were analyzed by in situ hybridization (ISH) and quantitative reverse transcription polymerase chain reaction (qRT-PCR) assays. Ectopic overexpression of miR-10b-3p in ESCC cells, mouse xenograft model, and metastasis model were used to evaluate the effects of miR-10b-3p on proliferation, and migration of cancer cells. Luciferase reporter assay and Western blot were performed to validate the potential targets of miR-10b-3p after the preliminary screening by computer-aided microarray analysis.

resultsWe found that miR-10b-3p expression levels were significantly upregulated in the tumor tissues and serum samples of patients with ESCC. The expression levels of miR-10b-3p in both tumor tissues and serum samples were inversely associated with lymph node metastasis and clinical stages. We identified the expression level of miR-10b-3p in ESCC cancer samples as an independent prognostic marker of the overall survival rates of ESCC patients. We found more frequent hypomethylation of the CpG sites located upstream of the miR-10b-3p gene in the ESCC tissues compared with in the adjacent normal tissues, and the DNA methylation status of miR-10b-3p promoter region inversely correlated with the expression levels of miR-10b-3p. Ectopic overexpression of miR-10b-3p promoted cell proliferation, colony formation, migration and invasion in ESCC. While knockdown of miR-10b-3p had the opposite effects, particularly in promoting apoptosis. Mouse xenograft model confirmed that miR-10b-3p functions as a potent oncogenic miRNA in ESCC, which also promoting ESCC metastasis. Mechanistically, we found miR-10b-3p regulated FOXO3 expression by directly binding to the 3'-untranslated region. And systemic delivery of miR-10b-3p antagomir reduced tumor growth and inhibit FOXO3 protein expression in nude mice.

conclusionsCollectively, our findings suggested upregulated expression of miR-10b-3p caused by promoter hypomethylation contributed to the progression of ESCC; Thus, miR-10b-3p is a potentially effective biomarker for ESCC that could have further therapeutic implications.

Indexed as

DNA MethylationAnimalsCell Line, TumorChromosomes, Human, Pair 2Disease Models, AnimalDisease ProgressionEsophageal Squamous Cell CarcinomaFemaleForkhead Box Protein O3HumansMiceMice, NudeMicroRNAsMiddle AgedNeoplasm InvasivenessPromoter Regions, GeneticForkhead Box Protein O3FOXO3 protein, humanMicroRNAsMIRN10 microRNA, humanBiomarkerEsophageal squamous cell carcinomaHypomethylationmicroRNAsTherapeutic target

Identifiers

PMID30514328
PMCPMC6280546
OpenAlexW2902453388

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.